Chanchal Sadhu

Chanchal Sadhu has a diverse and extensive work experience in the field of biotechnology and pharmaceuticals.

Starting in 1988, Chanchal worked as a Postdoctoral Associate at The Scripps Research Institute. The role lasted until 1990.

Following that, Chanchal joined ICOS Corporation in 1990 as a Staff Scientist. Here, Chanchal made significant contributions, including the discovery of the first inhibitor against Phosphatidyl Inositol 3-Kinase delta (PI3 K delta), which was later developed by Gilead Sciences as Idelalisib. Chanchal also played a key role in characterizing and developing monoclonal antibodies.

After seven years at ICOS Corporation, Chanchal then transitioned to the role of Sr. Scientist at ICOS Corp. from 1998 to 2007. Here, Chanchal discovered and characterized antibodies against CD18 family of integrins, as well as small molecules against protein tyrosine kinases.

Chanchal then moved on to Covance Laboratories in 2007, where they served as a Sr. Principal Investigator. At Covance Laboratories, Chanchal was responsible for the bioanalytical aspects of antibody and growth factor drug development. Chanchal developed and validated numerous assays for clinical and non-clinical testing.

In 2010, Chanchal accepted a role as Sr. Scientist II at Teva Biopharmaceuticals USA. At Teva, Chanchal directed bioassays and immunoassays for a late-stage product, as well as managed cell-based potency assays for multiple biologics.

Subsequently, Chanchal worked at MedImmune as a Sr. Scientist from 2015 to 2016. Here, Chanchal harmonized bioanalytical processes and supervised release and stability testing of biopharmaceuticals.

From 2016 to 2018, Chanchal held the position of Director, Bioanalytics at Novartis Pharmaceuticals. In this role, Chanchal managed personnel and processes in a bioanalytical lab, oversaw method development and validation, and played a crucial role in product testing and submissions.

Chanchal then joined Audentes Therapeutics in 2018 as Director, Bioanalytics. At Audentes, Chanchal built and led a Translational Sciences team focusing on genetic therapies for neurological disorders. Chanchal also established strong relationships with key stakeholders and collaborators.

Most recently, Chanchal has taken on the role of VP, Translational Research at Voyager Therapeutics, Inc. starting in 2022.

Chanchal Sadhu completed a PhD in Microbiology and Cell Biology from the Indian Institute of Science (IISc) between the years 1979 and 1984. Prior to that, Chanchal earned an M.Sc. in Microbiology and Biochemistry from Uttarakhand Jobs from 1976 to 1979. Additionally, Chanchal holds a Bachelor of Science (Hons.) degree with a major in Chemistry, Zoology, and Botany from Visva-Bharati University in Santiniketan, India, though the exact dates of this degree are unknown.